South Korea · Delayed Price · Currency is KRW ABL Bio Statistics
Total Valuation
ABL Bio has a market cap or net worth of KRW 3.98 trillion. The enterprise value is 3.87 trillion.
| Market Cap | 3.98T |
| Enterprise Value | 3.87T |
Important Dates
The next estimated earnings date is Tuesday, November 10, 2026.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ABL Bio has 55.99 million shares outstanding. The number of shares has increased by 14.30% in one year.
| Current Share Class | 55.99M |
| Shares Outstanding | 55.99M |
| Shares Change (YoY) | +14.30% |
| Shares Change (QoQ) | +0.50% |
| Owned by Insiders (%) | 25.76% |
| Owned by Institutions (%) | 11.07% |
| Float | 41.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 15,900.44 |
| PS Ratio | 115.95 |
| PB Ratio | 22.85 |
| P/TBV Ratio | 23.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 112.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.72, with a Debt / Equity ratio of 0.32.
| Current Ratio | 1.72 |
| Quick Ratio | 1.69 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.18 |
| Interest Coverage | -53.77 |
Financial Efficiency
Return on equity (ROE) is -44.26% and return on invested capital (ROIC) is -23.58%.
| Return on Equity (ROE) | -44.26% |
| Return on Assets (ROA) | -20.79% |
| Return on Invested Capital (ROIC) | -23.58% |
| Return on Capital Employed (ROCE) | -49.29% |
| Weighted Average Cost of Capital (WACC) | 5.67% |
| Revenue Per Employee | 336.11M |
| Profits Per Employee | -770.89M |
| Employee Count | 102 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.63% in the last 52 weeks. The beta is 0.27, so ABL Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -20.63% |
| 50-Day Moving Average | 82,120.00 |
| 200-Day Moving Average | 145,146.00 |
| Relative Strength Index (RSI) | 41.34 |
| Average Volume (20 Days) | 333,331 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ABL Bio had revenue of KRW 34.28 billion and -78.63 billion in losses. Loss per share was -1,424.72.
| Revenue | 34.28B |
| Gross Profit | 34.17B |
| Operating Income | -86.12B |
| Pretax Income | -79.17B |
| Net Income | -78.63B |
| EBITDA | -82.19B |
| EBIT | -86.12B |
| Loss Per Share | -1,424.72 |
Balance Sheet
The company has 167.08 billion in cash and 55.45 billion in debt, with a net cash position of 111.63 billion or 1,993.92 per share.
| Cash & Cash Equivalents | 167.08B |
| Total Debt | 55.45B |
| Net Cash | 111.63B |
| Net Cash Per Share | 1,993.92 |
| Equity (Book Value) | 173.94B |
| Book Value Per Share | 3,062.61 |
| Working Capital | 70.85B |
Cash Flow
In the last 12 months, operating cash flow was -41.76 billion and capital expenditures -5.32 billion, giving a free cash flow of -47.08 billion.
| Operating Cash Flow | -41.76B |
| Capital Expenditures | -5.32B |
| Depreciation & Amortization | 3.93B |
| Net Borrowing | 11.85B |
| Free Cash Flow | -47.08B |
| FCF Per Share | -840.95 |
Margins
Gross margin is 99.67%, with operating and profit margins of -251.20% and -229.36%.
| Gross Margin | 99.67% |
| Operating Margin | -251.20% |
| Pretax Margin | -230.93% |
| Profit Margin | -229.36% |
| EBITDA Margin | -239.74% |
| EBIT Margin | -251.20% |
| FCF Margin | n/a |
Dividends & Yields
ABL Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.30% |
| Shareholder Yield | -14.30% |
| Earnings Yield | -1.98% |
| FCF Yield | -1.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for ABL Bio is 257,500.00, which is 262.68% higher than the current price. The consensus rating is "Buy".
| Price Target | 257,500.00 |
| Price Target Difference | 262.68% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 2.72% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ABL Bio has an Altman Z-Score of 42.01 and a Piotroski F-Score of 1.
| Altman Z-Score | 42.01 |
| Piotroski F-Score | 1 |